ABBISKO-B (02256) announced that its pharmaceutical division, ABBISK Medicine, presented six latest preclinical and translational medicine research findings at the 2026 American Association for Cancer Research (AACR) Annual Meeting held in San Diego, USA, from April 17 to 22. The presentations, delivered in poster format, covered multiple core innovation areas of the company, including the pan-KRAS inhibitor ABSK211, the fourth-generation EGFR inhibitor ABK-EGFR-1, the selective CDK4 inhibitor ABK-CDK4, the PRMT5-MTA synergistic inhibitor ABSK131, and a study analyzing the resistance mechanism of the FGFR2/3 inhibitor ABSK061 using ctDNA technology. Research results indicated that ABSK211 can significantly enhance anti-tumor efficacy through multiple synergistic mechanisms, supporting its subsequent advancement into clinical development in combination with various therapeutic strategies. The findings also support the further development of ABK-EGFR-1 as a next-generation targeted therapeutic for EGFR-resistant tumors, particularly suitable for patients with brain metastases. ABK-CDK4 has the potential to overcome key limitations of current CDK4/6 inhibitors and offer a differentiated treatment option. ABSK131 is expected to become a core foundational therapy in combination treatment strategies for MTAP-deficient tumors. Through these presentations at the 2026 AACR Annual Meeting, ABBISK Medicine showcased the latest progress across multiple product pipelines, demonstrating the company's robust capabilities in early-stage drug discovery and development. As early-stage pipelines gradually advance into clinical phases, the company continues to enhance its globally competitive R&D platform. Moving forward, ABBISK Medicine will remain focused on addressing unmet clinical needs, accelerating the translation of innovative achievements into clinical applications, and delivering more innovative therapies with first-in-class and best-in-class potential to patients worldwide.
Comments